Publications by authors named "J G Rosenstock"
Article Synopsis
- Amyloidosis derived from apolipoprotein C-II (AApoCII) is a rare condition that primarily affects the kidneys, presenting with symptoms like proteinuria and reduced kidney function, particularly in older patients.
- A study conducted with 25 cases from the Mayo Clinic revealed common histological characteristics, such as nodular amyloid deposits in glomeruli, and proteomic analysis identified specific Apo C-II variants in many patients.
- Despite significant kidney issues, including end-stage kidney disease in about half of the patients, the overall survival rate was more favorable, indicating potential for better outcomes in this condition.
Background: Continuous glucose monitoring (CGM) can provide a comprehensive assessment of glycaemic control. This exploratory analysis of the ONWARDS 1 trial assessed CGM-based metrics and CGM-derived hypoglycaemia duration in insulin-naive individuals with type 2 diabetes treated with subcutaneous once-weekly insulin icodec (icodec) versus once-daily insulin glargine U100 (glargine U100).
Methods: ONWARDS 1 was a 78-week (52-week main treatment phase and a 26-week treatment extension phase plus a 5-week follow-up), randomised, open-label, treat-to-target, phase 3a trial done at 143 sites (outpatient clinics and hospital departments) across 12 countries.
Article Synopsis
- * It was previously thought that the risk of acute kidney injury (AKI) from ALCS was low due to minimal systemic absorption, but recent reports indicate a potential risk, though they often feature complicating factors.
- * A case study is presented where a patient experienced severe AKI requiring dialysis due to high tobramycin levels after using an ALCS with increased antibiotic dosing; this situation underscores the risks of nephrotoxicity, emphasizes careful antibiotic selection, and highlights the need for
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.
Cardiovasc Diabetol
September 2024
Aims: To estimate the incidence of major adverse cardiovascular events (MACE), expanded MACE, and MACE or Death across Fibrosis- 4 score (FIB-4) categories in people with type 2 diabetes and to determine whether efpeglenatide's effect varies with increasing FIB-4 severity.
Materials And Methods: AMPLITUDE-O trial data were used to estimate the relationship of FIB-4 score categories to the hazard of MACE, expanded MACE, and MACE or death. Interactions on these outcomes between baseline FIB-4 score, and between FIB-4 score and efpeglenatide were also assessed.